GGrantIndex
← Search

Developmental Funds

$215,358P30FY2025CANIH

University Of Wisconsin-Madison, Madison WI

Investigators

Linked publications, trials & patents

Paper 39638850Paper 39604703Paper 39580301Paper 39530524Paper 39527745Paper 39516197Paper 39484544Paper 39481346Paper 39474803Paper 39462136Paper 39452931Paper 39444276Paper 39443360Paper 39432401Paper 39414902Paper 39408582Paper 39407431Paper 39402986Paper 39399121Paper 39386576Paper 39386545Paper 39379374Paper 39374311Paper 39364328Paper 39358429Paper 39345631Paper 39335130Paper 39312186Trial NCT06608511Trial NCT06557733Trial NCT05985681Trial NCT05521698Trial NCT05107219Trial NCT03725761Trial NCT03722030Trial NCT03703492Trial NCT03656276Trial NCT03393741Trial NCT03387514Trial NCT03358563Trial NCT03356470Trial NCT03342378Trial NCT03304002Trial NCT03300557Trial NCT03209869Trial NCT03185871Trial NCT03028584Trial NCT03023202Trial NCT02955043Trial NCT02917629Trial NCT02876640Trial NCT02780401Trial NCT02719821Trial NCT02169284Trial NCT02096783Trial NCT02095145Trial NCT01999881Trial NCT01935960Trial NCT01901835Trial NCT01707004Trial NCT01625156Trial NCT01325311Trial NCT01263613Trial NCT01245205Trial NCT01243359Trial NCT01233505Trial NCT01218620Trial NCT01217450Trial NCT01158274Trial NCT01083641Trial NCT01004796Trial NCT00896974Trial NCT00666562Trial NCT00544596Trial NCT00499135Trial NCT00462969Trial NCT00415025Trial NCT00410605Trial NCT00227513Trial NCT00138203Trial NCT00109863Trial NCT00079014Trial NCT00052832Trial NCT00049712Trial NCT00036790Trial NCT00028652Trial NCT00023855Trial NCT00022412Trial NCT00005794Trial NCT00004872Patent 9867974Patent 9763597Patent 9603567Patent 9470697Patent 9161720Patent 8871458Patent 6974254Patent 6438202Patent 6114119Patent 6020178

Abstract

PROJECT SUMMARY – DEVELOPMENTAL FUNDS Our strategic plan re-envisions a road map for developmental fund investments, which will further advance our current trajectory of NCI funding (>30% increase), peer-reviewed training and education project funding (21% increase), treatment intervention accrual (44% increase), and productive and impactful membership recruitments (10% increase in members). Successful investments in the prior grant period led to $8.3M ($740K CCSG) towards the recruitment of 42 faculty. New UWCCC recruits have been awarded a total of approximately $103M in sponsored research funding. Among the new UWCCC recruitments; 29 focus on center disease priorities; 35- 40% are underrepresented minorities (URMs), 21 hold peer-reviewed cancer funding; 11 hold NCI funding; 23 filled active leadership roles; 25 are placed in UWCCC space; and 30 are active Shared Resource users. CCSG developmental funds will provide the Director with an ability to fiscally underwrite opportunities that further strategic goals, which includes recruitments in immunotherapy; transdisciplinary theranostics; population science, specifically in prevention; clinical informatics big data; and genomics translational science. UWCCC CCSG developmental funds provided resources of $1.8M for 75 pilot projects that aligned with our prior strategic plan goals. Going forward, pilot projects will be essential to catalyze inter- and intra-programmatic discovery. Building on the success of an increase in P and U mechanism awards (133% increase), we anticipate CCSG pilot funds focusing on cancer opportunities for additional program projects or SPORE applications. In addition, an emerging critical mass of researchers in cancer immunotherapy might eventually lead to a new program in this area. Therefore, pilots and start-up investments in immunotherapy are necessary for this goal in the UWCCC strategic plan. As a promotion of institutional authority, Dr. Bailey and the cancer center now (2022) have the authority to initiate (with a departmental partner) 1-2 tenure track faculty searches per year based on UWCCC priorities. Our center commits CCSG developmental funds for start-up support for faculty candidates who provide the most promising opportunities for significant contributions to the scientific programs, our catchment, our community, and to trainees. Our center actively recruits candidates who foster and promote the values of diversity and inclusion. UWCCC’s predominant catchment diseases, and subsequent priority investments, include the following: prostate, breast, head and neck, and blood cancers, including leukemia and myeloma. Going forward the center will place greater emphasis on inter-programmatic activities, disease specific pilot opportunities, and scientific retreat programming meant to stimulate research opportunities in disease priorities.

View original record on NIH RePORTER →